Christopher P. Austin, M.D., named director of NCATS
The mission of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions.
The Cures Acceleration Network (CAN) was authorized to advance the development of high need cures and reduce significant barriers between research discovery and clinical trials. To achieve these objectives, CAN provides the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) with new flexibilities in its funding authorities.
The Critical Path Initiative (CPI) is FDA’s national strategy to drive innovation in the scientific processes through which medical products are developed, evaluated, and manufactured.
The Initiative was launched in March 2004, with the release of FDA’s landmark report Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. The publication diagnosed the reasons for the widening gap between scientific discoveries that have unlocked the potential to prevent and cure some of today’s biggest killers, such as diabetes, cancer, and Alzheimer’s, and their translation into innovative medical treatments.